Genmab sales of Darzalex exceed expectations in Q3

Third quarter sales figures for Darzalex, which Genmab has in-licensed to Johnson & Johnson, are far better than previous estimates.

Photo: Joost Melis / Genmab / PR

The Genmab-developed treatment for multiple myeloma, a type of bone marrow cancer, has exceeded expectations in the third quarter of the year, according to Q3 reports from Johnson & Johson, which obtained the drug through an in-licensing agreement.

In June, August and September, Darzalex sales have have earned USD 1.58bn compared to analysts' earlier estimates of USD 1.45bn, according to data collected by Bloomberg News.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs